IP Library Granted Patent US 9,353,099
Granted Patent B2
US 9,353,099 · App. 14/742,556 · Granted May 31, 2016

Compounds that modulate intracellular calcium

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,353,099
App. No.
14/742,556
Granted
May 31, 2016
Kind
B2
Abstract

Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity.

Claims (26)

1. A compound of Formula (VI) having the structure:

wherein:

R′ 1 is,

L 2 is —NH—C(═O)—, or —C(═O)NH—;

Y is independently selected from CR 9 or N;

R 2 is phenyl, pyridyl, benzoxazolyl, or thiadiazolyl; wherein phenyl, pyridyl, benzoxazolyl, or thiadiazolyl is optionally substituted with at least one R 3 ;

R 3 is independently selected from H, F, D, Cl, Br, I, —CN, —NO 2 , —OH, —CF 3 , —OCF 3 , —OR 5 , C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, C 1 -C 6 haloalkyl,

n is an integer selected from 0-3;

R 9 is independently selected from H, D, halogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, —OR 5 , —OCF 3 , C 1 -C 6 carbonylalkyl, or —CF 3 ;

R 10 is selected from halogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, —OR 5 , —OCF 3 , C 1 -C 6 carbonylalkyl, or —CF 3 ;

R 5 is independently selected from H, C 1 -C 6 alkyl, and C 1 -C 6 haloalkyl;

or a pharmaceutically acceptable salt, or pharmaceutically acceptable solvate thereof.

2. A compound selected from:

or a pharmaceutically acceptable salt, or pharmaceutically acceptable solvate thereof.

3. A pharmaceutical composition comprising a pharmaceutically acceptable diluent, excipient or binder, and a compound of claim 1 or pharmaceutically acceptable salt, or pharmaceutically acceptable solvate thereof.

4. The compound of claim 1 wherein R′1 is

5. The compound of claim 1 wherein R′ 1 is

6. The compound of claim 1 wherein L 2 is —NH—C(═O)—.

7. The compound of claim 1 wherein Y is CR 9 .

8. The compound of claim 7 wherein R 9 is H.

9. The compound of claim 1 wherein n is 0.

10. The compound of claim 1 wherein R 2 is phenyl optionally substituted with at least one R 3 .

11. The compound of claim 1 wherein R 2 is benzoxaolyl optionally substituted with at least one R 3 .

12. The compound of claim 11 wherein heteroaryl is pyridine.

13. The compound of claim 11 wherein heteroaryl is thiadiazole.

14. The compound of claim 10 wherein R 3 is halogen.

Assignments (2)
SECURITY INTEREST Recorded Mar 4, 2025
From: CALCIMEDICA, INC.
To: AVENUE CAPITAL MANAGEMENT II, L.P.
Reel/Frame 070394/0314 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2015
From: WHITTEN, JEFFREY P.; PEI, YAZHONG; CAO, JIANGUO; WANG, ZHIJUN; ROGERS, EVAN; DYCK, BRIAN; GREY, JONATHAN
To: CALCIMEDICA, INC.
Reel/Frame 037022/0291 →